The Claim
In patients with atherosclerotic cardiovascular disease who are already on statin therapy, evolocumab provides consistent cardiovascular benefits across key subgroups, including those with low baseline LDL cholesterol levels (median 74 mg/dL), suggesting that further lowering of LDL cholesterol confers clinical benefit even when baseline levels are close to current treatment targets.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Even if your cholesterol is already pretty low thanks to statins, adding a drug called evolocumab can still help protect your heart and blood vessels.
See the scientific wording
The cardiovascular benefits of evolocumab in patients with atherosclerotic cardiovascular disease on statin therapy are consistent across key subgroups, including those with the lowest baseline LDL cholesterol levels (median 74 mg/dL), indicating that further LDL-C lowering provides clinical benefit even when baseline levels are near current treatment targets.
What the research says
1 studyStudy: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
The study tested a drug called evolocumab in heart disease patients already taking statins and found it helped prevent heart problems, even in people who already had relatively low 'bad' cholesterol.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.